Tara Gregory

Efficacy and Safety of P-Bcma-101 CAR-T Cells in Patients with Relapsed/Refractory (r/r) Multiple Myeloma (MM)

Tara Gregory, Adam D. Cohen, Caitlin Costello et al. · Blood · 2018 · 104 citations

Medicine, Hematology, Immunology +14

Phase 1/2 Study of the Safety and Response of P-BCMA-101 CAR-T Cells in Patients with Relapsed/Refractory (r/r) Multiple Myeloma (MM) (PRIME) with Novel Therapeutic Strategies

Caitlin Costello, Adam D. Cohen, Krina K. Patel et al. · Blood · 2020 · 76 citations

Medicine, Hematology, Immunology +15

BMS-986393 (CC-95266), a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from a Phase 1 Study

Susan Bal, Myo Htut, Omar Nadeem et al. · Blood · 2023 · 56 citations

Medicine, Immunology, Oncology +17

Phase 2 Study of the Response and Safety of P-Bcma-101 CAR-T Cells in Patients with Relapsed/Refractory (r/r) Multiple Myeloma (MM) (PRIME)

Caitlin Costello, Tara Gregory, Syed Abbas Ali et al. · Blood · 2019 · 53 citations

Medicine, Hematology, Oncology +16

Clinical Activity of BMS-986393 (CC-95266), a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients with Relapsed and/or Refractory (R/R) Multiple Myeloma (MM): First Results from a Phase 1, Multicenter, Open-Label Study

Susan Bal, Mehmet H. Kocoglu, Omar Nadeem et al. · Blood · 2022 · 39 citations

Medicine, Hematology, Oncology +17